Corporate Member Roster


       PlatCorpMem       

PlatGenentechLogo 
 

PlatNovoNordiskLogo 
 

PlatTakedaLogo 
 
       PlusCorpMem       

PlusAventineLogo 

PlusBayerLogo 

PlusIntarciaLogo 
     
PlusJohnsonJohnsonLogo 
 
PlusMylanLogo 
 
PlusSandozLogo 
 
     

ClickHereDetails on corporate levels can be found in the corporate membership section. 
     
                 


   AbbVie

 
www.abbvie.com
Bonnie Shaul, MBA
Director, Managed Healthcare Payer Strategy
(847) 937-5397
bshaul@abbvie.com

AbbVie is a global, research-based biopharmaceutical company formed in 2013 following separation from Abbott Laboratories. The company's mission is to use its expertise, dedicated people and unique approach to innovation to develop and market advanced therapies that address some of the world's most complex and serious diseases. Together with its wholly-owned subsidiary, Pharmacyclics, AbbVie employs more than 28,000 people worldwide and markets medicines in more than 170 countries. For further information on the company and its people, portfolio and commitments, please visit www.abbvie.com. Follow @abbvie on Twitter or view careers on our Facebook or LinkedIn page.
 


   ACADIA Pharmaceuticals Inc.

 
www.acadia-pharm.com
Mark Bubany
Senior Director Access, Pricing & Advocacy
(858) 863-1089
mbubany@acadia-pharm.com

At ACADIA (NASDAQ: ACAD), we share a passion for improving the lives of patients with central nervous system (CNS) disorders. Our vision is to become the leading pharmaceutical company dedicated to the advancement of innovative medicines that improve the lives of patients with CNS disorders. Our history is rooted in science and strong leadership in CNS research. We have set ourselves apart by transforming our novel discoveries into important drug candidates that may make a meaningful impact on the lives of patients and the family members who care for them every day.
 


   Acorda Therapeutics, Inc.

 
www.acorda.com
Steven Sandor
Vice President, Market Access
(914) 326-5373
ssandor@acorda.com

Acorda Therapeutics is a biotechnology company developing therapies for spinal cord injury, multiple sclerosis and related nervous system disorders. The Company's marketed products include Zanaflex Capsules® (tizanidine hydrochloride), a short-acting drug for the management of spasticity. Acorda filed a New Drug Application (NDA) for its lead clinical product, Fampridine-SR, on January 30, 2009. Clinical trials of Fampridine-SR evaluated its safety and efficacy in improving walking ability in people with MS. The Company's pipeline includes a number of products in development for the treatment, regeneration and repair of the spinal cord and brain.
 


   ALK Inc.

 
www.alk.net
Douglas Waddell, BS
Director MHC & Government Markets
(518) 441-3188
douglas.waddell@alk.net

As a world leader in allergy immunotherapy, ALK works to improve quality of life for the many allergy sufferers whose disease remains uncontrolled despite the use of symptom-relieving medication, by developing products that provide long-lasting relief. The company has approximately 2,000 employees, with subsidiaries, production facilities and distributors worldwide. ALK is headquartered in Denmark and listed on NASDAQ Copenhagen (OMX: ALK B).
 


   Alkermes

 
www.alkermes.com
Jason Voegele
Senior National Managed Markets Director - West
(949) 233-0818
jason.voegele@alkermes.com

Alkermes is a fully integrated biopharmaceutical company that applies its scientific expertise and technological know-how to develop innovative medicines designed to yield better therapeutic outcomes for patients with central nervous system (CNS) disorders, including addiction, schizophrenia and depression.
 


   Allergan PLC

 
www.allergan.com
Doug Fernandes
VP, Payer Marketing & Strategic Pricing
(862) 261-7000
doug.fernandes@allergan.com

Allergan, Inc. is a global specialty pharmaceutical company that develops and commercializes innovative products for the eye care, neuromodulator, skin care, obesity and other specialty markets. In addition to its discovery-to-development research programs, Allergan has global marketing and sales capabilities in over 100 countries that deliver value to our customers, satisfy unmet medical needs and improve people’s lives. Driven by technology and innovation, Allergan addresses the needs of consumers across the world with over 8,000 employees worldwide, 4 world-class Research and Development facilities and 5 state-of-the-art manufacturing plants.
 


   Amarin Pharma, Inc.

 
www.amarincorp.com
Todd Grisco
Vice President, Managed Markets and Trade
(908) 326-1310
todd.grisco@amarincorp.com

Amarin Corporation plc is a biopharmaceutical company focused on the commercialization and development of therapeutics to improve cardiovascular health. Amarin’s product development program leverages its extensive experience in lipid science and the potential therapeutic benefits of polyunsaturated fatty acids. Amarin's clinical program includes commitment to providing grants to support research and education in the disease state including the funding of an ongoing outcomes trial. Vascepa® (icosapent ethyl), Amarin’s first FDA approved product, is a highly-pure, EPA-only, omega-3 fatty acid product availably by prescription. For more information about Vascepa visit www.vascepa.com. For more information about Amarin visit www.amarincorp.com.
 


   AmerisourceBergen/Xcenda

 
www.amerisourcebergen.com
Matthew Sarnes, PharmD
Senior Vice President, Xcenda
(727) 771-4100 x4024
msarnes@xcenda.com

Xcenda is a premier full-service consultancy and leading managed markets agency whose experienced consulting team helps manufacturers identify, demonstrate, and deliver their brand’s value proposition to all healthcare stakeholders. For 15 years, Xcenda has been an essential partner, offering both strategic guidance and field support, to global pharmaceutical, device, and diagnostic companies, as well as emerging pre-commercialization phase firms. Clients who partner with Xcenda access marketers, health outcomes researchers, epidemiologists, reimbursement strategists, market research experts, managed care decision makers, and clinicians who bring a breadth of expertise across payer, provider, and patient segments. In addition, as Xcenda is part of AmerisourceBergen Corporation, our clients benefit from greater access to an integrated and comprehensive range of specialty distribution and commercialization support services.
 


   Amgen, Inc.

 
www.amgen.com
Larry Green, PharmD
Director, Global Scientific Communications
(805) 447-3010
lgreen@amgen.com

The world’s largest biotechnology company, Amgen Inc. discovers, develops, and delivers important human therapeutics based on advances in cellular and molecular biology including EPOGEN® (Epoetin alfa), Aranesp® (darbepoetin alfa), NEUPOGEN® (Filgrastim), Neulasta® (pegfilgrastim), Enbrel® (etanercept), Kineret® (anakinra) and Sensipar® (cinacalcet HCl). Amgen’s dedication to science and innovation is driven by a commitment to serving patients.
 


   Apobiologix, a division of ApoPharma USA

 
www.apobiologix.com
James Van Lieshout
VP Market Access and Pharmacy Strategy
(303) 444-9102
jvanlies@apotex.com

Apotex Inc. was founded in 1974, and is the largest Canadian-owned pharmaceutical company. From its 2 employees, 5,000 square foot beginning, the company has grown to employ over 10,000 people in research, development, manufacturing and distribution facilities world-wide. The Canadian operations of the Apotex Group of Companies has approximately 5,500 employees. Extensive investments in Canadian facilities include over 3 million square feet in manufacturing and R&D facilities in Richmond Hill, Toronto, Etobicoke, Brantford, Windsor and Winnipeg. Apotex produces more than 300 generic pharmaceuticals in approximately 4,000 dosages and formats which, in Canada, are used to fill over 89 million prescriptions a year - the largest amount of any pharmaceutical company in this country.
 


   Argus Health Systems, Inc.

 
www.argushealth.com
Kristy Cayot
Marketing Manager
(816) 843-5832
kristy.cayot@argushealth.com

Argus Health Systems, Inc., is the leading independent provider of health care information management services supporting commercial, Medicaid and Medicare Part D. Argus serves a wide range of clients and key health care organizations including managed care organizations, pharmacy benefit managers and pharmaceutical manufacturers. Argus was established in 1983, and by 1986 was a pioneer in electronic claims processing. Since then Argus has grown to become one of the largest pharmacy claims processors in the industry. In 2013, Argus processed more than 605 million claims, including one in five of all Medicare Part D claims nationwide. Argus is a wholly-owned subsidiary of DST Systems, Inc., headquartered in Kansas City, Mo. We also have customer relationships in every state in the country. Argus has been a catalyst for change in the pharmacy benefit management industry. Our unique business model is based on the values of integrity and honesty that frame our relationships with our clients. What we have offered our clients from the start—full disclosure, program control and aligned objectives—is now becoming the business model of choice. Our business model provides full disclosure and is transparent, with no fees or competing hidden business relationships. Consistent with our mission and values, Argus’ programs are fully auditable. Argus is free from industry bias and conflicts of interest—and has been recognized as an industry leader in these areas. Argus does not compete with our customers for business, act as a plan sponsor, nor do we own or have ownership in a mail order distribution facility. By not owning or operating a mail-service pharmacy, we have no reason to give advice regarding plan design that is biased toward a mail-service benefit. Such independence gives us the opportunity to be a leader in a fully transparent pharmacy benefit model for our customers and further the cause for industry transparency, reducing costs, and providing quality care.
 


   Astellas Pharma US, Inc.

 
www.us.astellas.com
Steve Steinhagen
Associate Director, Operations: Health Systems
(847) 317-8880
steve.steinhagen@us.astellas.com

Launched in April 2005, Astellas was formed by the historical merger of Japan’s third and fifth largest pharmaceutical companies- Yamanouchi, founded in 1923, and Fujisawa, founded in 1894. Created from a partnership of two respected, leading global companies, Astellas is built on a strategic platform focused in select therapeutic areas: Cardiology, Dermatology, Immunology, Infectious Disease, Oncology and Urology. Within each therapeutic area, Astellas focuses on unsurpassed science and building networks of trust among physicians, patients and partners. Key strategic products include: Prograf, VESIcare, Lexiscan, Adenoscan, Protopic, Amevive, AmBisome and Mycamine.
 


   Avalere Health, LLC

 
www.avalere.com
Leigh Ann Bruhn
Director
(202) 459-6284
lbruhn@avalere.com

Avalere Health is a strategic advisory company whose core purpose is to create innovative solutions to complex healthcare problems. Based in Washington, D.C., the firm delivers actionable insights, business intelligence tools and custom analytics for leaders in healthcare business and policy. Avalere's experts span 230 staff drawn from Fortune 500 healthcare companies, the federal government (e.g., CMS, OMB, CBO and the Congress), top consultancies and nonprofits. The firm offers deep substance on the full range of healthcare business issues affecting the Fortune 500 healthcare companies. Avalere's focus on strategy is supported by a rigorous, in-house analytic research group that uses public and private data to generate quantitative insight. Through events, publications and interactive programs, Avalere insights are accessible to a broad range of customers. For more information, visit avalere.com, or follow us on Twitter @avalerehealth.
 


   Aventine Consulting, LLC

   Corporate Member Plus

 
www.aventine-consulting.com
Holly Carlton Trautman, BA, MS, PharmD
Chief Operating Officer
(781) 290-8422
holly@aventine-consulting.com

Aventine is a consulting firm specializing in the development of formulary submission dossiers and economic modeling and comprised of a strategic team of highly experienced managed care clinicians who understand the needs of the payer audience. Our team leverages our past professional experience on the payer side of the access equation to create dossiers and models that are fit for purpose. We develop scientifically-sound, evidence-based, high-quality deliverables supporting the true value of our clients’ products and have decades of experience communicating to the US payer audience. Our team prides itself on the integrity of our work, the trusted relationships we have forged with our clients, and our high rate of returning customers. Since Aventine’s inception in 2008, our strong reputation as a personable and accountable boutique consulting firm has become one of our greatest professional assets. Ask around – our active client base includes companies of all sizes: from small start-ups, to biotechs, to large pharma companies in the top 5 by global sales revenue. For more information about our services and professional experience, please visit aventine-consulting.com.
 


   Bayer HealthCare

   Corporate Member Plus

 
www.bayerhealthcare.com
Ryan Morris
Regional Account Executive
(801) 462-5386
ryan.morris@bayer.com

From world-renowned pharmaceutical products to high-tech platforms, from innovative diagnostics technologies to veterinary medicines – Bayer HealthCare is a globally researching healthcare company.
 


   Biogen

 
www.biogen.com
Sarah Egerhei
Senior Manager, Payer & Channel Marketing
sarah.egerhei@biogen.com

Through cutting-edge science and medicine, Biogen discovers, develops and delivers to patients worldwide innovative therapies for the treatment of neurodegenerative diseases, hematologic conditions and autoimmune disorders. Founded in 1978, Biogen is one of the world’s oldest independent biotechnology companies and patients worldwide benefit from its leading multiple sclerosis and innovative hemophilia therapies. For product labeling, press releases and additional information about the company, please visit www.biogen.com.
 


   Bioventus LLC

 
www.bioventusglobal.com
Dan Rindner
Sr. Manager, Market Access
(919) 474-6724
dan.rindner@bioventusglobal.com

Our mission is to partner with the health care community to help people resume and enjoy active lives. To this end, we develop and/or market clinically proven and cost-effective orthobiologic solutions for bone fusion and osteoarthritis that are backed by clinical data. Thousands of physicians worldwide view their Bioventus representative as an extension of their practices, trusting them with helping in their patients’ care program and alleviating some of their administrative burdens. Bioventus’ adherence to high quality standards, its commitment to evidence-based medicine and its strong ethical behavior makes the company a trusted partner.
 


   Boehringer Ingelheim Pharmaceuticals, Inc.

 
www.boehringer-ingelheim.com
Kristen Binaso, RPh, CCP, FASCP
Sr. Assoc Director, Patient Advocacy & Prof Relations
(203) 798-5758
kristen.binaso@boehringer-ingelheim.com

The Boehringer Ingelheim group is one of the world’s 20 leading pharmaceutical companies. Headquartered in Ingelheim, Germany, it operates globally with 145 affiliates and more than 44,000 employees. Since it was founded in 1885, the family-owned company has been committed to researching, developing, manufacturing and marketing novel medications of high therapeutic value for human and veterinary medicine. As a central element of its culture, Boehringer Ingelheim has a demonstrated commitment to corporate social responsibility. Involvement in social projects, caring for employees and their families, and providing equal opportunities for all employees form the foundation of the global operations. Mutual cooperation and respect, as well as environmental protection and sustainability are intrinsic factors in all of Boehringer Ingelheim’s endeavors. In 2011, Boehringer Ingelheim achieved net sales of about $17.1 billion (13.2 billion euro). R&D expenditure in the business area Prescription Medicines corresponds to 23.5% of its net sales. For more information, please visit http://us.boehringer-ingelheim.com and follow us on Twitter at http://twitter.com/boehringerus.
 


   Bristol-Myers Squibb Company

 
www.bms.com
Alma Howard
Director Midwest Region Value Access & Payment
(954) 240-1747
alma.howard@bms.com

Our company’s mission is to extend and enhance human life by providing the highest-quality pharmaceutical and related health care products. We pledge – to our patients and customers, to our employees and partners, to our shareholders and neighbors, and to the world we serve – to act on our belief that the priceless ingredient of every product is the honor and integrity of its maker. Aligned with our mission, Bristol-Myers Squibb Managed Markets team is dedicated to supporting the important role managed care plays in extending and enhancing human life.
 


   Celgene Corporation

 
www.celgene.com
George Malouly
Sr. Market Access Exec
(310) 995-0175
gmalouly@celgene.com

Celgene is a global integrated biopharmaceutical company focused on the discovery, development and commercialization of innovative therapies designed to treat cancer and immunoinflammatory diseases. Celgene is dedicated to work closely with health care providers to assure patients in need have safe access to our drugs. The Company is also proud of the important benefits that our therapies bring to patients, of the Company’s demonstrated commitment to rapidly advance its promising new therapies through development so many more patients can be helped, and of the breadth of its programs to ensure that no American is denied access as a result of lack of resources. The ongoing development of our broad and deep proprietary pipeline of immunomodulatory agents (IMiDs®), cell-signaling inhibitors, as well as cellular and tissue therapeutics may allow Celgene to provide physicians worldwide with a more comprehensive and integrated set of therapeutic solutions for managing complex human diseases.
 


   Celldex Therapeutics

 
www.celldex.com
Anthony Marchetta
Associate Director of Access, Strategy & Services
(908) 323-2250
amarchetta@celldex.com

Celldex Therapeutics (NASDAQ: CLDX) was founded based on a fundamental scientific belief that harnessing the power of the immune system would break significant barriers in drug development for a host of devastating diseases. The Company’s pipeline is comprised of therapeutic antibodies, antibody drug conjugates, immune system modulators and vaccines that we believe have a higher probability of success because they are targeted to specific patient populations with high unmet medical need whose diseases express specific markers—including many underserved or completely un-served orphan indications. This has created a leading pipeline in immunotherapy comprised of two candidates in pivotal trials, one in brain cancer and one in triple negative breast cancer, four additional clinical candidates in a range of difficult-to-treat indications and a robust preclinical engine.
 


   Chiesi USA

 
www.chiesiusa.com
Marc Claussen
Director, Market Access
(317) 773-0695
marc.claussen@chiesi.com

Chiesi USA is a specialty pharmaceutical company committed to research, development, production and commercialization of innovative products in the areas of cardiovascular, respiratory, neonatology, rare disease and special care therapeutics. Our primary focus is on people: the people we serve in the healthcare community; the people whose lives are touched by our products and services; and the people who work at Chiesi USA, as they strive to build their company, their family and their community.
 


   Collegium Pharmaceutical, Inc.

 
www.collegiumpharma.com
Kevin Statz
Director, Marketing and Strategy
(781) 232-0742
kstatz@collegiumpharma.com

Collegium is a specialty pharmaceutical company focused on developing a portfolio of products that incorporate its patent-protected DETERx technology platform for the treatment of chronic pain and other diseases. The DETERx oral drug delivery technology is designed to provide extended-release delivery, unique abuse-deterrent properties, and flexible dose administration options. Collegium’s lead product candidate, Xtampza ER, is an abuse-deterrent, extended-release, oral formulation of oxycodone, in development for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate. Collegium developed Xtampza using its proprietary DETERx technology platform to address common methods of abuse, including chewing, crushing and/or dissolving, and then taking it orally or snorting or injecting.
 


   Conduent

 
www.conduent.com
Amy Cully
Clinical Pharmacist
(716) 572-5734
Amy.cully@xerox.com

As the world’s largest business process services company, we’re improving the way businesses and governments interact with their citizens, patients, customers and employees. Our mission is to modernize the constituent experience by making every interaction digital, personalized and secure. Every day we engage in relentless pursuit of greater solutions. We make a difference in the lives of millions every day.
 


   CVS Health

 
www.caremarkrx.com
Gary A. Loeber, BS Pharmacy
Principal
(847) 559-3817
gary.loeber@cvshealth.com

CVS Caremark is the largest provider of prescriptions in the nation. The Company fills or manages more than 1 billion prescriptions annually. Through its unmatched breadth of service offerings, CVS Caremark is transforming the delivery of health care services in the U.S. The Company is uniquely positioned to effectively manage costs and improve health care outcomes through its more than 6,900 CVS/pharmacy and Longs Drugs stores; its Caremark Pharmacy Services division (pharmacy benefit management, mail order and specialty pharmacy); its retail-based health clinic subsidiary, MinuteClinic; and its online pharmacy, CVS.com. General information about CVS Caremark is available through the Investor Relations section of the Company's Web site, at www.cvscaremark.com/investors, as well as through the press room section of the Company's Web site, at www.cvscaremark.com/newsroom.
 


   Daiichi Sankyo, Inc.

 
www.dsi.com
Mrs. Tara Mautone, BA
Director, Managed Markets Operations
(973) 944-2640
tmautone@dsi.com

Daiichi Sankyo, Inc., headquartered in Parsippany, New Jersey, is the U.S. subsidiary of Japan-based Daiichi Sankyo Co., Ltd., one of the twenty largest pharmaceutical companies in the world and a global leader in pharmaceutical innovation since 1899. The company is dedicated to the discovery, development and commercialization of innovative medicines that improve the lives of patients throughout the world. The primary focus of Daiichi Sankyo’s research and development is cardiovascular disease, including therapies for dyslipidemia, hypertension, diabetes, and acute coronary syndrome. The company is also pursuing the discovery of new medicines in the areas of glucose metabolic disorders, infectious diseases, cancer, bone and joint diseases, and immune disorders. For more information, visit www.dsus.com.
 


   Diplomat

 
www.diplomat.is
Scott Sorenson
Director, Government
(704) 246-6646
ssorenson@diplomat.is

Diplomat is the nation’s largest independent specialty pharmacy, bringing personalized medication therapies to people with specialized needs such as oncology, inflammatory and autoimmune conditions, HCV, blood disorders and more. We offer innovative tools to help patients, including starter kits for side-effect management and our proprietary CarePak™ for easy dose tracking. Our systems and skillsets complement patient care—complete benefits investigations, dedicated efforts for prior authorizations and PA appeals, start-to-finish third-party funding assistance and Medicare support. As a teammate in health, we also offer back-end patient support services for national retailers and major hospitals and specialty-care coverage to millions of lives through managed care organizations.
 


   Eisai, Inc.

 
www.eisai.com
Allen Waxman
Exec. VP and General Counsel Market Access/Law & Government Affairs
(201) 746-2750
allen_waxman@eisai.com

Eisai Inc. is supported by a strong parent company, Eisai Co., Ltd., which was founded in Japan in 1941 as Nihon Eisai Co., Ltd. To this day, Eisai Co., Ltd. is one of the few Japanese pharmaceutical companies to undertake aggressive global expansion through substantial infrastructure investments in its foreign affiliates. These affiliates conduct research and development, manufacturing, and sales and marketing in the United States, Europe and Asia. Globally, most of Eisai’s sales are derived from treatments for central nervous system diseases and gastrointestinal disorders. Eisai has more than 7,000 employees worldwide and is a publicly traded company whose stock trades on the Tokyo and Osaka exchanges and in the United States under an American Depository Receipt with the ticker symbol of ESALY.
 


   EMD Serono Inc.

 
www.emdserono.com
John Neal
VP Marketing, Managed Markets
(781) 681-2040
john.neal@emdserono.com

EMD Serono, Inc. is committed to discovering and developing medicines that address unmet medical needs. EMD Serono focuses its business in the areas of neurology, reproductive health, metabolic endocrinology, oncology, and autoimmune disease, integrating innovative science with comprehensive patient support systems to improve lives. Visit us at www.emdserono.com.
 


   Exelixis, Inc.

 
www.exelixis.com
Mr. Michael McDole, MBA
Senior National Account Director
(303) 548-8949
mdmcdole@hotmail.com

Exelixis, Inc., from the Greek word for “evolution,” is a biopharmaceutical company committed to developing and commercializing small molecule therapies with the potential to improve the treatment of cancer. Over the past decade, we have established a broad development platform, laying the foundation for our continued efforts to bring new therapies for cancer to patients in need. The history of our lead compounds, cabozantinib and cobimetinib, tells the story of our evolution as a company. Each of these compounds were discovered in our own laboratories and advanced by us into clinical development. Exelixis was founded and incorporated in 1994 and we are based in South San Francisco, California. Exelixis is dedicated to improving the care of, and outcomes for patients with cancer.
 


   Express Scripts

 
www.express-scripts.com
Jody H. Allen, BS, PharmD, FASHP
VP, Clinical Account Management, Health Plans
(804) 814-8937
jody_allen@express-scripts.com

At Express Scripts, we help make the use of prescription drugs safer and more affordable. It's been our mission since 1986, when a group of healthcare advocates began applying the rigors of scientific research to the pharmacy benefit. With the country facing hundreds of billions of dollars of prescription-related waste each year from costly drug, pharmacy and health choices, our mission remains as relevant as ever. We are passionate about gleaning insights from data and translating those insights into solutions. We test and learn our way toward the most comprehensive set of solutions to drive out prescription-related waste and help improve health outcomes. We provide best-in-class pharmacy benefit management (PBM) services and industry-leading home delivery and specialty pharmacy services for our diverse client base.
 


   Fresenius Medical Care North America

 
www.fmcna.com
Jeff Maxwell
Vice President, PharmaTech
(781) 699-4522
jeff.maxwell@fmc-na.com

Providing direct renal services to over 167,000 ESRD patients, Fresenius Medical Care (FMCNA) is the largest provider of renal therapy services and products in the United States. We manufacture and distribute the leading dialysis products and equipment and other dialysis_related supplies. Fresenius Medical Cared North Americas pharmaceutical offering includes, Velphor®, Venofer® & Phoslyra®.
 


   Genentech Inc.

   Platinum Corporate Member

 
www.gene.com
David Barhoum
(425) 879-5309
barhoumd@gene.com

Genentech, Inc. is a leading biotechnology company focusing on the discovery, development, manufacture, and marketing of pharmaceuticals for significant, unmet medical needs. Genentech’s managed care specialists are committed to enhancing the quality and delivery of patient care by working with managed care organizations to find effective solutions to health care issues.
 


   Gilead Sciences, Inc.

 
www.gilead.com
Jim Ziegler
Sr. Director Market Access
(650) 522-5618
Jim.Ziegler@gilead.com

Gilead Sciences is a biopharmaceutical company that discovers, develops and commercializes innovative therapeutics in areas of unmet medical need. The company's mission is to advance the care of patients suffering from life-threatening diseases worldwide. Headquartered in Foster City, California, Gilead has operations in North America, Europe and Australia. Visit Gilead on the World Wide Web at www.gilead.com.
 


   GSK

 
www.gsk.com
Fran M. Kochman, PD
Director, Advocacy & Alliance Development
(860) 668-9013
fran.m.kochman@gsk.com

GlaxoSmithKline (GSK), one of the world’s leading research-based health care companies, discovers, develops, manufactures and markets pharmaceuticals, vaccines, over-the-counter medications and health-related products. GSK’s people are committed to fighting disease by bringing innovative medicines and services to patients throughout the world and to the health care providers who serve them.
 


   Health Information Designs, LLC

 
www.hidllc.com
Kathleen Sabo
Director of Business Development & Marketing
(334) 466-3031
kathleen.sabo@hidesigns.com

Health Information Designs (HID) is a pharmacy services company that provides a comprehensive suite of prior authorization (PA) solutions to health plans and pharmacy benefit managers for promoting compliance monitoring, adherence, and criteria management. HID's clinical professionals -- pharmacists, physicians, and nurses -- know the industry, our products, and our clients. Our combined total of over 650 years of pharmacy experience provides the strong clinical foundation on which we build our solutions.
 


   Incyte Corporation

 
www.incyte.com
Rolli Greer
Associate Director, Access and Channel Marketing
(302) 498-5789
rgreer@incyte.com

Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics, primarily for oncology. The company’s first commercial product, Jakafi® (ruxolitinib), an oral JAK1 and JAK2 inhibitor, is approved by the FDA to treat two rare blood disorders--first approved in November 2011 Jakafi received a subsequent U.S. approval in December 2014. To learn about Jakafi, please visit www.Jakafi.com
 


   Insulet Corporation

 
www.insulet.com
Steve Bledsoe
Director, Managed Care
(978) 600-7000
sbledsoe@insulet.com

Insulet Corporation (NASDAQ: PODD) is an innovative medical device company dedicated to making the lives of people with diabetes easier. Through its OmniPod® Insulin Management System, Insulet seeks to expand the use of insulin pump therapy among people with insulin-dependent diabetes. The OmniPod® is a revolutionary and easy-to-use tubeless insulin pump that features just two parts and a fully-automated cannula insertion. Insulet's Delivery Systems business also partners with global pharmaceutical and biotechnology companies to tailor the OmniPod® technology platform for the delivery of subcutaneous drugs across multiple therapeutic areas. To read inspiring stories of people with diabetes living their lives to the fullest with OmniPod®, visit our customer blog, http://suited.myomnipod.com/. Founded in 2000, Insulet Corporation is based in Billerica, Massachusetts.
 


   Intarcia Therapeutics

   Corporate Member Plus

 
www.intarcia.com
Aria Cohen
Executive Director, Payer Strategy & Programs
(617) 936-2593
aria.cohen@intarcia.com

Intarcia Therapeutics, Inc., is a rapidly emerging biopharmaceutical company developing innovative therapies that merge medicine with technology, and have the potential to transform therapeutic categories. Our near-term goal is to enhance treatment outcomes for patients with type 2 diabetes by improving efficacy, continuous administration, and tolerability of drug therapies.
 


   Intercept Pharmaceuticals

 
www.interceptpharma.com
Keith White
US Head, Marketing Access and Reimbursement
(646) 747-1000
keith.white@interceptpharma.com

Intercept is a biopharmaceutical company focused on the development and commercialization of novel therapeutics to treat chronic liver diseases utilizing our proprietary bile acid chemistry. The advances we are making in the development of novel treatments for liver diseases such as primary biliary cirrhosis (PBC) and nonalcoholic steatohepatitis (NASH) have the potential to change the lives of patients and physicians who currently have few, if any, therapeutic options.
 


   Johnson & Johnson Health Care Companies

   Corporate Member Plus

 
www.jnj.com
William J. Johnson, MBA
National Account Director
(847) 726-9962
wjohnso2@its.jnj.com

Johnson & Johnson Health Care Companies are committed to creating measurable value for our managed markets customer through a dedicated focus on meeting your needs. In doing so, we will draw on our wide range of innovative products and services. We can work together to improve your clinical and business outcomes.
 


   Lexicon Pharmaceuticals

 
www.lexgen.com
George Rodriguez
Senior Director, Strategic Accounts
(813) 340-2809
grodriguez@lexpharma.com

Lexicon Pharmaceuticals is a biopharmaceutical company focused on the development of breakthrough treatments for human disease. We have advanced multiple drug candidates into clinical development. We are presently devoting most of our resources to the development of our two most advanced drug candidates, LX4211 for the treatment of type 1 and type 2 diabetes and Telotristat etiprate (LX1032/LX1606) for the treatment of carcinoid syndrome.
 


   Lilly USA, LLC

 
www.lilly.com
John H. Poulin, MBA
Director, Professional Relations
(317) 277-8173
jhpoulin@lilly.com

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquarted in Indianapolis, IN, Lilly provides answers – through medicines and information – for some of the world’s most urgent medical needs.
 


   Magellan Rx Management

 
www.magellanrx.com
Steve Michurski
SVP, PBM Trade Relations
(480) 624-9339
smichurski@magellanhealth.com

At Magellan Rx Management, we are a full-service pharmacy benefits manager (PBM) that specializes in solving complex pharmacy challenges for our customers. We believe in developing and executing smart solutions that leverage our industry-leading experience and technology to exceed expectations across the following lines of business: Employer, Third Party Administrator, Broker; Managed Care; Government, Medicaid, Medicare Part D. As a pioneer in medical specialty pharmacy management and a leader in best-in-class formulary optimization programs, we deliver consistent, proven cost savings. As clinical experts, we deliver customized programs to address our clients’ most pressing clinical challenges, drive STAR improvements, and engage patients and providers to deliver improved health outcomes. elcome to a unique vision of care. Magellan Rx Management is a division of Magellan Health, Inc.
 


   Mallinckrodt

 
www.mallinckrodt.com
Teresa Herrell
Market Access
(314) 654-5820
teresa.herrell@mallinckrodt.com

Mallinckrodt is a global specialty pharmaceutical company. Focus areas include therapeutic drugs for autoimmune and rare-disease specialty areas along with analgesics and central nervous system drugs for prescribing by office- and hospital-based physicians. Mallinckrodt’s Specialty Pharmaceuticals segment includes branded and specialty generic drugs and active pharmaceutical ingredients.
 


   MedHOK

 
www.medhok.com
Michelle Frank
Chief Growth Officer
(888) 963-3465
mfrank@medhok.com

MedHOK (Medical House of Knowledge) offers a single integrated platform for Care, Quality and Compliance. Developed for PBMs, Health Plans, and ACOs, MedHOK supports over 26 million covered lives. For Part D Plans, MedHOK’s integrated CMS-compliant modules include: Electronic Prior Authorization, Appeals, Grievances, Complaints Tracking, MTM, Rx Specialty Management and Direct Member Reimbursement.
 


   MedImpact Healthcare Systems, Inc.

 
www.medimpact.com
Gordon Romanas
Vice President, Marketing
(858) 790-6475
gordon.romanas@medimpact.com

MedImpact Healthcare Systems, Inc. (http://www.medimpact.com), founded in 1989 and headquartered in San Diego, Calif., is a full-service pharmacy benefit management (PBM) company that combines subject matter expertise with innovative technology and services to deliver better healthcare outcomes and improve its clients’ positions in the market. MedImpact provides PBM services to 47 million members of health plans, hospitals and employers in the U.S. and abroad. MedImpact’s model is unique: avoiding conflict of interest by deriving revenue from effectively managing client pharmacy benefits rather than dispensing drugs.
 


   Merck & Co., Inc.

 
www.merck.com
Jody A. Shollenberger
Assoc. Director
(267) 305-2481
jody_shollenberger@merck.com

Today's Merck is a global healthcare leader working to help the world be well. Merck is known as MSD outside the United States and Canada. Through our prescription medicines, vaccines, biologic therapies, and consumer care and animal health products, we work wtih customers and operate in more than 140 countries to deliver innovative health solutions. We also demonstrate our commitment to increasing access to healthcare through far-reaching policies, programs and partnerships. For more information, visit www.merck.com.
 


   Mirixa Corporation

 
www.mirixa.com
Kim Swiger, BS Pharmacy
Vice President, Product Development
(703) 865-2031
kswiger@mirixa.com

Mirixa Corporation is a leading healthcare technology and services company. Mirixa identifies and connects patients with trusted pharmacists and other healthcare providers for individualized medication counseling. Mirixa’s innovative technology and services improve patients’ health and reduce costs.
 


   Momenta Pharmaceuticals, Inc.

 
www.momentapharma.com
Heather Knapp
Associate General Counsel
(617) 395-2854
Hknapp@momentapharma.com

Momenta is a leader in the analysis, characterization, and design of complex pharmaceutical products. Our scientific foundation is a set of tools and methods that enable one to develop a deep understanding of the links between a compound’s chemical structure, its manufacturing process and its biological function. We are applying our innovative technology to the development of generic versions of complex drugs, biosimilar and potentially interchangeable biologics, and to the discovery and development of novel therapeutics for oncology and autoimmune indications. Our success is a result of our committed and talented people. We attract scientists exceptionally skilled in integrating information from diverse technical disciplines and task them with challenging characterization, process, and biology problems. Using this approach, we have designed tools and methods to understand the structure (characterization of chemical components), structure-process (design and control of manufacturing process) and structure-activity (relationships between structure and biological and clinical activity) of complex mixture drugs. From this knowledge comes a diversified product development pipeline consisting of complex generics, biosimilars and novel drugs designed to address a variety of medical needs.
 


   Mylan Inc.

   Corporate Member Plus

 
www.mylan.com
Rameshwari Bhavsar, PharmD
Account Supervisor
(215) 962-8260
rameshwari.bhavsar@mylan.com

Mylan is one of the world’s leading generics and specialty pharmaceutical companies, providing products to customers in more than 150 countries and territories. The company maintains one of the industry’s broadest and highest quality product portfolios, which is regularly bolstered by an innovative and robust product pipeline.
 


   NaviSync, LLC

 
www.navisyncllc.com
Bill Kelly
President
(973) 845-9970
bill.kelly@navisyncllc.com

The health care environment is becoming more complex, with commercial and government payers attempting to control how health care is practiced and influence market perceptions about products, coverage, or services. NaviSync is a full-service managed markets company providing intelligent sound strategy to increase access to your brand through the utilization of actionable insights gleaned from payers, hospitals, and alternative care settings. Efficiently delivered market intelligence is critical to attaining payer access and achieving commercial success. We tackle access and reimbursement challenges for top-tier pharmaceutical/biotechnology companies, including specialty market products.
 


   NovaBay Pharmaceuticals

 
www.novabay.com
Greg Miller
Director, Strategic Sales
(720) 325-3099
gmiller@novabay.com

NovaBay Pharmaceuticals, Inc. is a biopharmaceutical company developing products for the eye care market. We are currently focused primarily on commercializing prescription Avenova® for managing hygiene of the eyelids and lashes in the United States. Avenova is the only eye care product formulated with a proprietary, stable and pure form of hypochlorous acid called Neutrox®. By replicating the anti-microbial chemicals used by white blood cells to fight infection, Neutrox has proven in laboratory testing to have broad antimicrobial properties. In addition to our Neutrox family of products, we have also synthesized and developed a second category of novel compounds aimed at harnessing the power of white blood cell chemistry to address the global, topical anti-infective market. This second product category includes auriclosene, our lead clinical-stage Aganocide® compound, which is a patented, synthetic molecule with a broad spectrum of activity against bacteria, viruses and fungi.
 


   Novartis Pharmaceuticals Corporation

 
www.pharma.us.novartis.com
Erik Maietta
Convention Manager
(862) 778-2964
erik.maietta@novartis.com

Novartis Pharmaceuticals Corporation is committed to improving health and quality of life by focusing on the discovery, development, manufacture and marketing of innovative, effective and safe prescription medications. Key therapeutic areas include Cardiovascular, Endocrine & Respiratory Diseases, Gastroenterology; Central Nervous System Disorders; Dermatology; Oncology/Hematology; Rheumatism/Bone & Hormone Replacement Therapy and Transplantation. Located in East Hanover, NJ, Novartis Pharmaceuticals is an affiliate of Novartis AG, a world leader in Healthcare in more than 140 countries with core businesses in pharmaceuticals, consumer health, generics, eyecare, and animal health.
 


   Novo Nordisk, Inc.

   Platinum Corporate Member

 
www.novonordisk-us.com
Kristie Raker, PharmD
Director, Professional Association Relations
(609) 786-4595
ksra@novonordisk.com

Novo Nordisk Inc. is a focused healthcare company. With a broad diabetes product portfolio, including innovative products within the area of insulin delivery systems, Novo Nordisk is a world leader in diabetes care. Novo Nordisk manufactures and markets pharmaceutical products and services that make a significant difference to patients, the medical profession, and society. Worldwide, Novo Nordisk employs an estimated 18,800 people in 69 countries and markets its products in 179 countries. Novo Nordisk's global headquarters is located in Denmark where the company began more than 80 years ago with the North American affiliate headquartered in Princeton, NJ.
 


   OptumRX

 
www.catamaranrx.com
David Calabrese, BS Pharmacy
VP, Clinical Services & Chief Pharmacy Officer
(224) 231-1813
David.calabrese@optum.com

OptumRx® is a pharmacy care services company with a flexible and innovative approach. Our combined company now connects more than 65 million Americans to improved care, lower costs and a better health care experience. Most traditional PBMs focus on distributing prescriptions and managing pharmacy costs. Our diverse and unique resources enable OptumRx to go beyond the prescription — and help our customers and members reduce total health care costs and improve health.
 


   OPKO

 
www.opko.com
Cristine A. Sproles, PharmD
Sr. Account Director
(317) 903-6870
csproles@opko.com

OPKO Health, Inc. is a diversified healthcare company that seeks to establish industry-leading positions in large, rapidly growing markets. Our diagnostics business includes Bio-Reference Laboratories, the nation’s third-largest clinical laboratory with a core genetic testing business and a 420-person salesforce to drive growth and leverage new products. Our pharmaceutical business features Rayaldee™, a treatment for secondary hyperparathyroidism in stage 3-4 chronic kidney disease patients with vitamin D deficiency (March 29, 2016 PDUFA date) and VARUBI™ for chemotherapy-induced nausea and vomiting. Our biologics business includes hGH-CTP, a once-weekly human growth hormone injection (in Phase 3 and partnered with Pfizer), and a long-acting Factor VIIa drug for hemophilia (entering Phase 2a). We also have production and distribution assets worldwide, multiple strategic investments and an active business development strategy.
 


   OutcomesMTM

 
www.outcomesmtm.com
Brand Newland
VP of Business Development
(515) 864-7944
bnewland@outcomesmtm.com

OutcomesMTM®, a Cardinal Health company, is the national leader in the design, delivery and administration of Medication Therapy Management (MTM) programs. The company’s service line helps healthcare purchasers advance patient care and utilization control through patient-friendly Personal Pharmacist™ services, demonstrating the Face-to-Face Difference® for their members. .
 


   PerformRx

 
www.performrx.com
John C. Butts
Director, Sales and Public Relations
(215) 937-8073
john.butts@performrx.com

PerformRx, LLC provides innovative, cost-effective pharmacy benefit management services for Medicaid, Medicare, and commercial health plans. Through a distinctive, hightouch approach, PerformRx partners with health plans to improve patient outcomes and financial performance. PerformRx bases its success on a clinical focus hat is driven by cuttingedge, proprietary technology.
 


   Pfizer Inc.

 
www.pfizer.com
John W. Main, PharmD
Senior Director Field Based Medical
(630) 634-3648
john.main@pfizer.com

As one of the world’s leading healthcare companies, Pfizer has developed and brought to market medicines for humans and animals for over 150 years. Our portfolio includes more category-leading medicines than any other company – treatments that are helping countless people everyday to ease arthritis and nerve pain, manage depression, fight diabetes and cancer and control hypertension. Our portfolio of innovative medicines currently includes treatments for more than a dozen disease areas and we are targeting unmet medical needs through state-of-the-art research and development. We know that healthcare is more than a business—it’s a mission-and our products can only help people if they can get them. That’s why we are deeply committed to enhancing access to high-quality healthcare. This year, through innovative partnership programs, Pfizer is giving product donations for patients in need around the world and building the infrastructure necessary to ensure that the medicines get to those who need it most. The value of medicine. The benefits of research. The commitment to help meet the needs of those in need. At Pfizer, we dedicate ourselves to humanity’s quest for longer, healthier, happier lives through innovation in pharmaceutical, consumer and animal health products.
 


   Pharmacy Quality Solutions, Inc.

 
www.pharmacyquality.com
Todd Sega, PharmD
Manager of Payer Relations
(919) 864-9756
tsega@pharmacyquality.com

Who We Are Pharmacy Quality Solutions, Inc. (PQS) is a joint venture created to fill the need to connect medication use stakeholders to quality information in a consistent and reliable fashion, allowing them to move more quickly from measurement to improvement. Our hallmark service is EQuIPP, the first national pharmacy quality measurement, benchmarking, and reporting platform for pharmacies and health plans. EQuIPP provides consistent and reliable measurement and reporting on key medication use quality measures, including those addressing medication adherence and patient safety, and makes this measurement available and easily understandable.
 


   Precision for Value

 
www.precisionforvalue.com
Larry Blandford, PharmD
Executive Vice President, Managing Partner
(908) 470-1780
larry.blandford@precisionformedicine.com

-Precision for Medicine, headquartered in Bethesda, MD, is a specialized company providing services and infrastructure to support life sciences companies as they develop new products in the age of precision medicine. Precision brings expertise, technology, and project execution to support innovative, patient-centric solutions from discovery through commercialization. www.precisionformedicine.com
-Precision for Value supports commercial excellence for global pharmaceutical and life sciences clients through the proficient demonstration of product value and outcomes. With locations in New York City, New Jersey, Chicago, Boston, Connecticut, and Indianapolis, Precision for Value’s teams provide clients with services grounded in decades of industry knowledge, demonstrated analytics proficiency, and marketing and communications prowess—making Precision for Value the preferred strategic partner in the industry. www.precisionforvalue.com
-Precision Advisors combines unrivaled real-world market experience with thought leadership and industry expertise to provide insight, strategy and advice to innovative life science companies. Headquartered in Cambridge, Massachusetts, Precision Advisors’ unmatched team of expert advisors encompass all areas of the commercialization spectrum including strategy consulting, managed markets, health economics, clinical research and analytics. www.pfmadvisors.com
-Precision for Medicine, headquartered in Bethesda, MD, is a specialized company providing services and infrastructure to support life sciences companies as they develop new products in the age of precision medicine. Precision brings expertise, technology, and project execution to support innovative, patient-centric solutions from discovery through commercialization. www.precisionformedicine.com"
 


   Prime Therapeutics LLC

 
www.primetherapeutics.com
Angela Seibert
Sponsorship & Events Manager
(612) 777-6207
aseibert@primetherapeutics.com

Prime Therapeutics is an independent pharmacy benefit manager that is committed to the health of those we serve. Our "people over profits" approach reflects our privately held heritage. We also believe it produces the best results. Our health care system is fragmented. Instead of working together, doctors, pharmacists, and insurers often focus only on their own pieces of the puzzle. Poor communication and lack of coordination cause errors and create gaps in care. Prime has a different view. Because we are collectively owned by non-profit health plans, we never forget that drugs are part of a bigger picture. We exchange pertinent data and insights with health plans and work with them to coordinate across pharmacy and medical benefits. We leverage our unique connections to deliver programs that lead to the best health outcomes.
 


   Purdue Pharma, L.P.

 
www.pharma.com
Craig Engesser
Associate Director, Healthcare Alliance Development
(203) 588-8000
craig.engesser@pharma.com

Purdue Pharma L.P. is well known for its pioneering work on persistent pain, a principal cause of human suffering. The company’s leadership and employees are dedicated to providing healthcare professionals, patients and caregivers with effective therapies, and innovative educational resources and tools that support their proper use.
 


   Relypsa, Inc.

 
www.relypsa.com
Neera Clase
Executive Director, Managed Markets
(650) 421-9640
nclase@relypsa.com

To improve patients’ lives through the discovery, development and delivery of therapeutics that leverage polymer science and other novel approaches.
 


   RxAdvance

 
www.rxadvance.com
Ravi Ika
President & CEO
(508) 804-6900
ravi.ika@rxadvance.com

RxAdvance is a national full service PBM (Pharmacy Benefit Manager), bringing superior clinical, pharmacy, and financial outcomes to plan sponsors through Collaborative PBM Cloud. Built on a unified data model and clinical intelligence, RxAdvance’s PBM standard services include Benefit and Formulary Design, Claims Processing, Customer Support Services, Retail Pharmacy Network Management, Clinical Services, and Rebate Management. Our market differentiation includes Drug Utilization Review at Point of Care (PoC) and Point of Sale (PoS), Medication Therapy (MTM) and Adherence Management (MAM), Donut Hole Prediction and Prescription Planner, Optimize Untapped Generics Usage, Prevent Adverse Drug Effects, Fraud, Waste and Abuse Management, Advanced Analytics and Cost Management, Maximize Mail Order Services, and Effective Specialty Management. RxAdvance enables real-time actionable communication between prescriber, pharmacist, patient, and payer. Our best in class People, Process and Technology are for all plan sponsors—health plans, Accountable Care Organizations (ACOs), state Medicaid programs, employer groups, and unions. We provide contractually guaranteed savings in administrative costs, unit costs, and rebate revenues.
 


   Sandoz

   Corporate Member Plus

 
www.sandoz.com
William Yoon, PharmD
National Director, Clinical Development and Medical Affairs
(602) 881-1280
william.yoon@sandoz.com

Sandoz is a world leader in generic pharmaceuticals, finding innovative ways to making medicines affordable and accessible to more than 90 percent of the world’s population.Sandoz prides itself on thinking differently. While developing and manufacturing high-quality affordable medicines is core to who we are and what we do, our mission is even greater: We endeavor to make these medicines available to everyone, everywhere. Our portfolio of approximately 1 100 molecules is already available to more than 90% of the world’s population and we continue to work hard to further increase global access.
 


   Sanofi

 
www.sanofi.com
James Caro
Senior Director, US Advocacy
(202) 585-3030
james.caro@sanofi.com

Sanofi-Aventis, a leading global pharmaceutical company, discovers, develops, and distributes therapeutic solutions to address the world’s expanding healthcare needs. We work to prevent and treat the diseases that we know of today, as well as those we may face tomorrow. With approximately 100,000 dedicated professionals in more than 100 countries, Sanofi-aventis is devoted to advancing healthcare around the world. We are committed to maintaining the innovative approach to pharmaceuticals established by our parent company, headquartered in Paris, France. Our U.S. affiliate, with headquarters in Bridgewater, New Jersey, employs approximately 12,000 professionals located throughout the country. Sanofi-aventis, U.S. is a dynamic healthcare organization working to meet the needs of physicians and their patients. At sanofi-aventis, each and every day we work for what really matters: health .For more information, visit www.sanofi-aventis.us
 


   Shire US Inc.

 
www.shire.com
Edward M. DePaz
VP, Head of Commercial Accounts
(484) 595-8801
edepaz@shire.com

Shire’s strategic goal is to become the leading specialty biopharmaceutical company that focuses on meeting the needs of the specialist physician. Shire focuses its business on attention deficit hyperactivity disorder (ADHD), human genetic therapies (HGT) and gastrointestinal (GI) diseases as well as opportunities in other therapeutic areas to the extent they arise through acquisitions. Shire’s in-licensing, merger and acquisition efforts are focused on products in specialist markets with strong intellectual property protection and global rights. Shire believes that a carefully selected and balanced portfolio of products with strategically aligned and relatively small-scale sales forces will deliver strong results. For further information on Shire, please visit the Company’s website: www.shire.com.
 


   Supernus Pharmaceuticals Inc.

 
www.supernus.com
Gary Ellexson
VP, Corporate Accounts
(301) 838-2557
gellexson@supernus.com

With more than 20 years of experience, we are a specialty pharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) disorders. We are developing several product candidates in neurology and psychiatry to address unmet medical needs and opportunities in epilepsy, attention-deficit hyperactivity disorder (ADHD) and its coexisting disorders, and depression. We are developing differentiated products by leveraging our proprietary and in-licensed technologies. We use such technologies to discover and develop novel uses for known drug compounds and to enhance their therapeutic benefits. Our focus on known drug compounds with established mechanisms of action reduces the risks, costs, and time typically associated with pharmaceutical product development.
 


   Taiho Oncology, Inc.

 
www.taihooncology.com
Michael Mitchell
Director, Market Access - Midwest
(908)285-3587
mmitchell@TaihoOncology.com

Taiho Oncology, Inc. (www.taihooncology.com), a division of Taiho Pharmaceutical Co., Ltd. and Otsuka Holdings Co., Ltd., has built a world class clinical development organization that works urgently to develop innovative cancer treatments and is in the process of building commercial businesses in the USA and Europe. Taiho’s oral oncology pipeline consists of both novel antimetabolic agents and selectively targeted agents.
 


   Takeda Pharmaceuticals U.S.A., Inc.

   Platinum Corporate Member

 
www.takeda.us
Timothy Mather
Director, Managed Markets Operations
timothy.mather@takeda.com

Based in Deerfield, IL, Takeda Pharmaceuticals, U.S.A., Inc and Takeda Development Center Americas, Inc. are subsidiaries of Takeda Pharmaceutical Company Limited, the largest pharmaceutical company in Japan. The respective companies currently market oral diabetes, respiratory and immunology, gastroenterology, central nervous system and obesity treatments and seek to bring innovative products to patients through a pipeline that includes compounds in development for metabolic and cardiovascular disease, central nervous system, oncology and other conditions. To learn more about Takeda companies and products, visit www.takeda.com.
 


   Teva Pharmaceuticals

 
www.tevausa.com
Travis Kenney, PharmD
Senior Manager, Health Systems Marketing
(913) 777-3095
travis.kenney@Tevapharm.com

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world's leading generic drug maker, with a global product portfolio of more than 1,000 molecules, sold in more than 100 countries, and with a direct presence in about 60 countries. Teva's specialty medicine businesses focus on CNS, including pain, respiratory, oncology, and women's health therapeutic areas as well as biologics. Teva currently employs approximately 45,000 people around the world and reached $20.3 billion in net revenues in 2013.
 


   The Access Group

 
www.theaccessgp.com
Seth Gordon
Managing Partner
(908) 508-6700
sgordon@frontiermmarkets.com

The Access Group is the leading independent strategic health care communications network composed of 7 distinct companies: Bioeclipse, Catalyst Medical Communications, FronTier Managed Markets, Fusion Medical Communications, MedAccess, Promidian, and StrataMed. The firm employs more than 95 health care marketing specialists and senior leaders with experience in management consulting, medical education, marketing communications, managed markets, training, and brand promotion. The Access Group is headquartered in Berkeley Heights, New Jersey, with offices in New York City, Chicago, Los Angeles, San Diego, and San Francisco. To learn more about our company, please visit www.theaccessgp.com or contact Seth Gordon, Managing Partner, at (908) 508-6700.
 


   TOLMAR Pharmaceuticals Inc.

 
www.tolmar.com
Steve Griffin
Vice President, Sales and Commercial Operations
(224) 880-5775
steve.griffin@tolmar.com

TOLMAR is a fully integrated company focused on the development, approval, and commercialization of specialty pharmaceutical products, including a line of generic dermatology products where TOLMAR is an established leader, and specialty injectable oncology products. Invention, development, and worldwide approval of ELIGARD® (leuprolide acetate for injectable suspension) for the palliative treatment of advanced prostate cancer has established TOLMAR as a leader dedicated to the urology community, providers, and patients. TOLMAR has 24 FDA-approved products.
 


   Upsher-Smith Laboratories, Inc.

 
www.upsher-smith.com
Mike McBride
AVP, Partner Relations
(763) 315-2173
mike.mcbride@upsher-smith.com

Upsher-Smith Laboratories, Inc., founded in 1919, is a growing, fully integrated pharmaceutical company dedicated to its mission of delivering high-value, high-quality therapies and solutions which measurably improve individuals’ lives. As a family-owned pharmaceutical company, we are able to adapt and thrive in a dynamic healthcare environment. Our world is constantly evolving, and we are continually adapting to the ever-changing needs of patients, physicians, pharmacists, and healthcare organizations. Where there is a need, we will work to deliver solutions that simplify access to treatment, deliver better health outcomes, and enhance life. Upsher-Smith has a particular focus on developing therapies for people living with central nervous system (CNS) conditions, such as seizure disorders. For more information, visit www.upsher-smith.com.
 


   ZS Pharma, Inc.

 
www.zspharma.com
David L. James
Director, Managed Markets
(650) 458-4100
djames@zspharma.com

ZS Pharma, founded in 2008, is a publicly traded biopharmaceutical company dedicated to challenging the status quo in disease states where therapeutic options have been limited. We are currently focused on using our proprietary ion­-trap technology to develop new treatments that are focused on addressing unmet needs in the medical community. From manufacturing to technology to people, ZS Pharma is thinking differently about developing therapies to address unmet needs.